FDAnews
www.fdanews.com/articles/72635-conor-initiates-costar-ii-trial-in-u-s

Conor Initiates COSTAR II Trial in U.S.

May 24, 2005

Conor Medsystems, a developer of innovative controlled vascular drug delivery technologies, announced that the first patient has been enrolled in the company's COSTAR II U.S. pivotal clinical trial.

The first patient procedure was performed by Dean Kereiakes, medical director of The Heart Center of Greater Cincinnati and The Lindner Clinical Trials Center in Cincinnati, and one of the principal investigators for the trial.

The COSTAR II trial (CObalt chromium STent with Antiproliferative for Restenosis) is designed to randomize approximately 1,700 patients at up to 75 U.S. sites and 15 international sites. It is a single-blind, noninferiority study comparing Conor's CoStar stent with Boston Scientific's Taxus Express2 drug-eluting stent in the treatment of de novo lesions in patients with single or multivessel coronary artery disease. Conor expects the data from this trial to support its application for U.S. regulatory approval of its CoStar cobalt chromium paclitaxel-eluting stent.